With the increased use of next-generation sequencing (NGS) to identify mutations in patient's own cancer cells, the off-label usage of non-approved drugs is on the rise. In this interview, Federico Cappuzzo, MD, PhD, of AUSL della Romagna, Ravenna, Italy, discusses the reasons why, and in what situations, his practice uses drugs off-label to treat lung cancer. This video was recorded in the 2018 European Lung Cancer Congress (ELCC), in Geneva, Switzerland.

свернуть